Eversept Partners LP Buys New Position in Agios Pharmaceuticals, Inc. $AGIO

Eversept Partners LP bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 200,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,766,000.

Other institutional investors have also recently bought and sold shares of the company. Quantinno Capital Management LP grew its stake in shares of Agios Pharmaceuticals by 2.7% during the 1st quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock worth $933,000 after acquiring an additional 736 shares in the last quarter. Pale Fire Capital SE lifted its position in shares of Agios Pharmaceuticals by 15.2% in the first quarter. Pale Fire Capital SE now owns 13,650 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 1,800 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Agios Pharmaceuticals during the first quarter worth $8,473,000. Knott David M Jr boosted its holdings in Agios Pharmaceuticals by 417.0% during the first quarter. Knott David M Jr now owns 93,058 shares of the biopharmaceutical company’s stock worth $3,148,000 after purchasing an additional 75,058 shares during the last quarter. Finally, Sei Investments Co. grew its position in Agios Pharmaceuticals by 342.8% in the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 49,198 shares in the last quarter.

Agios Pharmaceuticals Trading Up 1.7%

NASDAQ AGIO opened at $36.97 on Tuesday. The firm’s fifty day moving average price is $34.07 and its two-hundred day moving average price is $30.76. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The firm has a market capitalization of $2.20 billion, a P/E ratio of -5.10 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. The company’s quarterly revenue was up 137.7% on a year-over-year basis. On average, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.33 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AGIO shares. Royal Bank Of Canada lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. decreased their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Thursday, June 11th. The Goldman Sachs Group lifted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Truist Financial upped their target price on Agios Pharmaceuticals from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Bank of America increased their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $40.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.